search
Back to results

Bipolar Hemostatic Forceps Versus Standard Therapy in Acute Non-variceal Upper GI Bleeding (BeBop)

Primary Purpose

Gastrointestinal Hemorrhage

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Hemostatic therapy
Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Sponsored by
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastrointestinal Hemorrhage focused on measuring Hemostasis, Endoscopic; Randomized Controlled Trial

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Active, nonvariceal, upper gastrointestinal bleeding

Exclusion Criteria:

  • Severe coagulopathy unresponsive to blood products transfusions: platelets <20,000; international normalized ratio >3.0; partial thromboplastin time >2 normal

Sites / Locations

  • Helios Kliniken SchwerinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard therapy

Bipolar hemostatic forceps

Arm Description

Endoscopic therapy with hemoclip +/- injection of epinephrine solution

Endoscopic therapy with bipolar hemostatic forceps

Outcomes

Primary Outcome Measures

Successful primary hemostasis
Number of participants without further endoscopically visible gastrointestinal bleeding in esophagogastroduodonoscopy
Rebleeding
Number of participants without recurrent endoscopically visible gastrointestinal bleeding in esophagogastroduodonoscopy

Secondary Outcome Measures

Reinterventions
Number of endoscopic reinterventions for gastrointestinal bleeding

Full Information

First Posted
April 25, 2022
Last Updated
January 25, 2023
Sponsor
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Collaborators
PENTAX Europe GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT05353062
Brief Title
Bipolar Hemostatic Forceps Versus Standard Therapy in Acute Non-variceal Upper GI Bleeding
Acronym
BeBop
Official Title
Bipolar Hemostatic Forceps Versus Standard Therapy by Hemoclip and or Epinephrin Injection as Initial Endoscopic Treatment in Acute Non-variceal Upper GI Bleeding: a Prospective, Randomized Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2023 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
February 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Collaborators
PENTAX Europe GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Bipolar hemostatic forceps will be tested against standard therapy in active, non-variceal, upper gastrointestinal bleeding by a prospective, randomized trial
Detailed Description
Patients with active, non-variceal, upper gastrointestinal bleeding usually need an urgent endoscopic treatment. The standard therapy by application of an hemoclip and/or injection of an epinephrine solution is not always successful. Bipolar hemostatic forceps is already being used successfully for the treatment of gastrointestinal bleeding in endoscopic submucosal dissection. Its use in primary endoscopic treatment of non-variceal, upper gastrointestinal bleeding has not been shown yet in a randomized prospective study. Patients with active, non-variceal, upper gastrointestinal bleeding (esophagus or stomach or duodenum) of any cause are randomized (1:1) in standard therapy by combination therapy using an hemoclip and/or injection of an epinephrine solution or experimental therapy by application of the bipolar hemostatic forceps. Cross over-treatment should be tried first in case of failed initial treatment. Rescue treatment by other methods such as application of an Over the Scope Clip (OTSC), angiographic embolization or surgery will be allowed next. All patients receive an additional standard therapy by proton pump inhibitors (PPI). Hypothesis: Endoscopic therapy by application of the bipolar hemostatic forceps is superior to standard therapy regarding technical success and rebleeding rate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Hemorrhage
Keywords
Hemostasis, Endoscopic; Randomized Controlled Trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Randomized prospective study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard therapy
Arm Type
Active Comparator
Arm Description
Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Arm Title
Bipolar hemostatic forceps
Arm Type
Experimental
Arm Description
Endoscopic therapy with bipolar hemostatic forceps
Intervention Type
Procedure
Intervention Name(s)
Hemostatic therapy
Intervention Description
Bipolar hemostatic forceps
Intervention Type
Procedure
Intervention Name(s)
Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Intervention Description
Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Primary Outcome Measure Information:
Title
Successful primary hemostasis
Description
Number of participants without further endoscopically visible gastrointestinal bleeding in esophagogastroduodonoscopy
Time Frame
15 minutes
Title
Rebleeding
Description
Number of participants without recurrent endoscopically visible gastrointestinal bleeding in esophagogastroduodonoscopy
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Reinterventions
Description
Number of endoscopic reinterventions for gastrointestinal bleeding
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Active, nonvariceal, upper gastrointestinal bleeding Exclusion Criteria: Severe coagulopathy unresponsive to blood products transfusions: platelets <20,000; international normalized ratio >3.0; partial thromboplastin time >2 normal
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Schmitz, MD
Phone
+491758674415
Email
Daniel.Schmitz@helios-gesundheit.de
First Name & Middle Initial & Last Name or Official Title & Degree
Martin Kliment, MD
Phone
+493855202601
Email
Martin.Kliment@helios-gesundheit.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Schmitz, MD
Organizational Affiliation
Helios Kliniken Schwerin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Helios Kliniken Schwerin
City
Schwerin
ZIP/Postal Code
19055
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Schmitz, MD
Phone
+491758674415
Email
Daniel.Schmitz@helios-gesundheit.de
First Name & Middle Initial & Last Name & Degree
Martin Kliment, MD
Phone
+493855202601
Email
Martin.Kliment@helios-gesundheit.de

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data (IPD) will be available to other researchers on request
Citations:
PubMed Identifier
33567467
Citation
Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, Laursen SB, Radaelli F, Papanikolaou IS, Curdia Goncalves T, Dinis-Ribeiro M, Awadie H, Braun G, de Groot N, Udd M, Sanchez-Yague A, Neeman Z, van Hooft JE. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021 Mar;53(3):300-332. doi: 10.1055/a-1369-5274. Epub 2021 Feb 10.
Results Reference
result
PubMed Identifier
23468331
Citation
Kataoka M, Kawai T, Hayama Y, Yamamoto K, Nonaka M, Aoki T, Yagi K, Fukuzawa M, Fukuzawa M, Moriyasu F. Comparison of hemostasis using bipolar hemostatic forceps with hemostasis by endoscopic hemoclipping for nonvariceal upper gastrointestinal bleeding in a prospective non-randomized trial. Surg Endosc. 2013 Aug;27(8):3035-8. doi: 10.1007/s00464-013-2860-4. Epub 2013 Mar 7.
Results Reference
result

Learn more about this trial

Bipolar Hemostatic Forceps Versus Standard Therapy in Acute Non-variceal Upper GI Bleeding

We'll reach out to this number within 24 hrs